Praxis Precision Medicines, Inc.
NASDAQ Global SelectTotal Valuation
Praxis Precision Medicines, Inc. carries a market capitalization of 7.26B, placing it among publicly traded companies globally. Its enterprise value stands at 8.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.26B |
| Enterprise Value | 8.59B |
Share Statistics
Praxis Precision Medicines, Inc. currently has 27.92M shares outstanding.
| Shares Outstanding | 27.92M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 6.97 |
| P/TBV Ratio | 6.97 |
| P/FCF Ratio | -28.95 |
| P/OCF Ratio | -28.92 |
Financial Position
Praxis Precision Medicines, Inc. maintains a current ratio of 15.73, meaning it holds 15.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.73 |
| Quick Ratio | 15.46 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -38.86 |
| Return on Assets (ROA) | -36.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Praxis Precision Medicines, Inc.'s stock has gained approximately 48.60913% over the past 52 weeks. The 50-day moving average sits at 321.87, while the 200-day moving average is 315.70.
| Beta (5Y) | N/A |
| 52-Week Price Change | 48.60913% |
| 50-Day Moving Average | 321.87 |
| 200-Day Moving Average | 315.70 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -378.05M, while operating income came in at -378.17M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -378.17M |
| Pretax Income | -339.13M |
| Net Income | -339.13M |
| EBITDA | -378.05M |
| EBIT | -378.17M |
| Earnings Per Share (EPS) | -12.87 |
Balance Sheet
Praxis Precision Medicines, Inc. holds 758.55M in cash and equivalents against 1.09M in total debt, resulting in a net debt position of -474.76M. Total book value stands at 1.34B, with working capital of 722.85M providing operational flexibility.
| Cash & Cash Equivalents | 758.55M |
| Total Debt | 1.09M |
| Net Debt | -474.76M |
| Equity (Book Value) | 1.34B |
| Book Value Per Share | 48.04 |
| Working Capital | 722.85M |
Cash Flow
Praxis Precision Medicines, Inc. produced -305.08M in operating cash flow over the past twelve months. After subtracting -307,000.00 in capital expenditures, free cash flow totaled -305.38M - equivalent to -11.59 per share.
| Operating Cash Flow | -305.08M |
| Capital Expenditures | -307,000.00 |
| Free Cash Flow | -305.38M |
| FCF Per Share | -11.59 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -13.20 |
| FCF Yield | -3.45 |
Stock Splits
Praxis Precision Medicines, Inc.'s most recent stock split took place on November 29, 2023 with a 15:1 split ratio.
| Last Split Date | 11/29/2023 |
| Split Ratio | 15:1 |
Scores
Praxis Precision Medicines, Inc. posts an Altman Z-Score of 112.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 112.71 |